University of Massachusetts Medical School spinoff Apic Bio has raised seed capital from The Alpha-1 Project as it looks to develop a treatment for Alpha-1 Antitrypsin deficiency.
Apic Bio, a US-based gene therapy spinoff from University of Massachusetts Medical School (UMMS), launched yesterday with seed funding from The Alpha-1 Project (TAP), the investment arm of non-profit organisation Alpha-1 Foundation.
Apic Bio is developing treatments for rare diseases and is initially focusing on Alpha-1 Antitrypsin (A1AT) deficiency, a genetic condition that can lead to lung disease in adults and liver disease throughout a patient’s life.
The startup’s technology is based on research conducted by co-founder and chief scientific…